Editas Medicine Q1 EPS Forecast Lifted by Zacks Research

Editas Medicine, Inc. (NASDAQ:EDIT) – Investment analysts at Zacks Research increased their Q1 2025 earnings per share estimates for Editas Medicine in a report released on Wednesday, March 26th. Zacks Research analyst A. Chakraborty now expects that the company will earn ($0.63) per share for the quarter, up from their previous estimate of ($0.73). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Editas Medicine’s Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.68) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.62) EPS and Q4 2026 earnings at ($0.60) EPS.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Wednesday, March 5th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.16). Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The firm had revenue of $30.60 million for the quarter, compared to analyst estimates of $37.17 million. During the same period in the prior year, the company posted ($0.23) EPS.

A number of other brokerages also recently weighed in on EDIT. Royal Bank of Canada decreased their price target on Editas Medicine from $5.00 to $4.00 and set a “sector perform” rating for the company in a report on Friday, December 13th. Chardan Capital restated a “neutral” rating on shares of Editas Medicine in a research report on Friday, December 13th. Barclays lowered their target price on Editas Medicine from $5.00 to $3.00 and set an “equal weight” rating for the company in a report on Friday, December 13th. Evercore ISI cut their price target on Editas Medicine from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday, December 16th. Finally, Truist Financial lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $6.83.

Editas Medicine Stock Performance

NASDAQ:EDIT opened at $1.13 on Monday. Editas Medicine has a 52 week low of $1.12 and a 52 week high of $7.13. The firm’s fifty day moving average is $1.51 and its 200-day moving average is $2.12. The firm has a market cap of $93.76 million, a P/E ratio of -0.44 and a beta of 1.88.

Institutional Trading of Editas Medicine

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio lifted its stake in shares of Editas Medicine by 236.5% in the fourth quarter. Public Employees Retirement System of Ohio now owns 111,716 shares of the company’s stock valued at $142,000 after buying an additional 78,513 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Editas Medicine by 30.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,170,000 shares of the company’s stock worth $1,486,000 after acquiring an additional 272,467 shares during the last quarter. Two Sigma Advisers LP lifted its position in Editas Medicine by 46.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,657,000 shares of the company’s stock valued at $2,104,000 after acquiring an additional 528,000 shares in the last quarter. Two Sigma Investments LP boosted its stake in Editas Medicine by 21.4% during the 4th quarter. Two Sigma Investments LP now owns 1,649,072 shares of the company’s stock valued at $2,094,000 after purchasing an additional 290,483 shares during the last quarter. Finally, Tang Capital Management LLC bought a new stake in Editas Medicine during the 4th quarter worth approximately $508,000. Institutional investors own 71.90% of the company’s stock.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.